10 newer rulings cite the same tariff codes.

Classification can shift over time. Review the more recent rulings below before relying on this one.

G85956 G8 Ruling Active

The tariff classification of R149524, imported in bulk form, from Belgium

Issued January 25, 2001 by U.S. Customs and Border Protection.

Cite this ruling

Copies to clipboard

G8 G85956 (January 25, 2001)

Tariff classification

HTS codes: 2933.39.4100

Headings: 2933

Product description

The subject product, presently designated as R149524, is an investigational new drug (IND #60,186) currently undergoing Phase II clinical trials in the U.S. to evaluate its efficacy in the treatment of gastroesophageal reflux disease and diabetic gastroparesis. Pursuant to the general notice concerning guidance in the tariff classification of pharmaceutical products imported for clinical research (see Customs Bulletin and Decisions, Vol. 34, No. 21, May 24, 2000),

CBP rationale

the applicable subheading for the subject product will be 2933.39.4100, Harmonized Tariff Schedule of the United States (HTS), which provides for "[H]eterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: Other: Other: Drugs: Other.

Full text

NY G85956 January 25, 2001 CLA-2-29:RR:NC:2:238 G85956 CATEGORY: Classification TARIFF NO.: 2933.39.4100 Robert J. Leo, Esq. Meeks & Sheppard 330 Madison Avenue, 39th Floor New York, NY 10017 RE: The tariff classification of R149524, imported in bulk form, from Belgium Dear Mr. Leo: In your letter dated December 28, 2000, on behalf of your client, Janssen Pharmaceutica Products, LP, you requested a tariff classification ruling. The subject product, presently designated as R149524, is an investigational new drug (IND #60,186) currently undergoing Phase II clinical trials in the U.S. to evaluate its efficacy in the treatment of gastroesophageal reflux disease and diabetic gastroparesis. Pursuant to the general notice concerning guidance in the tariff classification of pharmaceutical products imported for clinical research (see Customs Bulletin and Decisions, Vol. 34, No. 21, May 24, 2000), the applicable subheading for the subject product will be 2933.39.4100, Harmonized Tariff Schedule of the United States (HTS), which provides for "[H]eterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: Other: Other: Drugs: Other." The rate of duty will be 6.5 percent ad valorem. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 212-637-7068. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Follow G85956

Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.

One email per day at most. Confirm your address once, unsubscribe anytime.

Searching CBP rulings the smart way

Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.